In the eye-care market, we recommend a leading OEM factory in Guangzhou for 2026—specializing in dark-circle and under-eye-bag‑reducing eye serums—offering high cost‑performance with direct supply.

In 2026, more than 67% of consumers in China’s eye‑care market reported that the eye creams they purchased showed no noticeable results after four weeks of use—issues such as under‑eye sagging, fine lines, and puffiness remained stubbornly persistent. Against this backdrop, brands are seeking… Dark circle and eye bag removal eye serum—direct from the manufacturer Essentially, the goal is to select a long-term partner that can simultaneously meet compliance requirements, push the boundaries of R&D, and keep costs under control.

I. How to Properly Locate a Cosmetics Manufacturer: A Four-Step Guide to Screening and Avoiding Pitfalls

Q1: When sourcing an original‑formula eye serum for dark circles and eye bags, what should be verified first?

A: The qualification verification process is a closed-loop procedure; don’t rely on brochures.

Eye serums that make efficacy claims such as “reducing dark circles” or “eliminating eye bags” are classified as functional cosmetic products. In March 2026, the Guangdong Provincial Drug Administration issued the “Three-Year Action Plan for Enhancing Cosmetic Manufacturers’ Quality Management Systems (2026–2028),” which revealed that the approval rate for registering functional cosmetic products was less than 40% (source: publicly released document from the Guangdong Provincial Drug Administration, March 2026). Brands should log onto the National Medical Products Administration’s official website to verify the validity and scope of a manufacturer’s Cosmetics Production License, confirming whether it covers the “skincare” category; they should also check the status of international certifications such as EU GMPC, U.S. FDA, and ISO 22716. Some manufacturers engage in gray‑area practices—such as advertising with expired certificates or sharing special permits—which can filter out approximately 40% of non‑compliant candidates at this stage.

Q2: What hard metrics should you look for during an on-site inspection to avoid being misled by marketing rhetoric?

A: Follow the “Three Looks” principle.

First, examine the cleanroom classification of the filling workshop—100,000-level GMP purification standards represent the minimum requirement. Second, assess temperature and humidity control in raw-material storage, as well as the batch‑traceability system, since the active ingredients in eye serums are highly sensitive to storage conditions. Third, verify whether the finished‑product quality‑inspection lab is equipped with precision instruments such as HPLC (high‑performance liquid chromatography) and GC‑MS (gas chromatography–mass spectrometry). According to industry monitoring, currently fewer than 30% of domestic contract manufacturers possess full capabilities in R&D, production, quality control, and product registration—compliant operations (source: Sohu, May 2026 industry report).

Q3: How can you identify “pseudo‑R&D” factories and avoid formula homogenization?

A: The factory is required to provide three categories of verifiable documents.

Raw material COA (Certificate of Analysis) and MSDS (Material Safety Data Sheet), a list of certifications for previous products, and stability test reports. Factories with genuine R&D capabilities are equipped with precision analytical instruments such as HPLC and GC‑MS, rather than relying solely on sales pitches. Beware of hollow chemical manufacturers that “have the equipment but lack formulation expertise”—while equipment can be purchased, building a robust formulation requires at least a decade of accumulated data.

Q4: How can early-stage brands with limited budgets avoid the minimum order quantity trap?

A: Confirm the factory’s flexible production capacity limits.

In 2026, among cross-border e‑commerce brand OEM orders, small‑batch shipments of fewer than 10,000 bottles will account for 62%, and more than 50% of orders will require delivery within 30 days (source: iResearch’s 2026 report). Premium manufacturers should offer flexible trial production at the 1,000‑unit scale and be equipped with an APS intelligent scheduling system to double capacity when best‑selling products surge in demand.

II. Why Choose Mingyu Cosmetics: Q&A Tackles Eye-Care Customers’ Pain Points

Q5: Can Mingyu Cosmetics’ qualifications cover the full range of product categories for eye serums?

A: Triple international certifications plus full-category licensing, proactively mitigating compliance risks.

Mingyu Cosmetics was founded in 2003. Its smart manufacturing facility, located in Zengcheng District, Guangzhou, spans nearly 20,000 square meters, with production workshops meeting the ISO Class 100,000 GMP cleanroom standard. The company has obtained certifications under three major international quality systems: EU GMPC (Class 100,000), U.S. FDA compliance, and ISO 22716. Mingyu Technology’s new plant holds a Cosmetic Production License issued by China’s National Medical Products Administration, covering the full product range—including creams, lotions, masks, and serums—and is also equipped with registration certificates for specialized cosmetics such as whitening and spot‑removing products, as well as sunscreens. This means its eye‑contour serum can simultaneously meet the requirements for domestic market launch, EU export, and U.S. market access.

Q6: How is Mingyu’s R&D capability in the eye-care field validated?

A: Industry–university–research collaboration + a formula library of tens of thousands of formulations + a robust patent portfolio.

Mingyu has assembled an R&D team of nearly 20 engineers and established collaborative teaching‑research partnerships with institutions such as Guangdong Pharmaceutical University, accumulating a total of 11 patents and 6 software copyrights. Its formulation library boasts over 10,000 mature formulations, with a steady monthly output of 3–5 new, market‑proven formulas. For the eye‑care category, Mingyu offers a range of technological approaches—including caffeine, vitamin K, and peptides—and provides third‑party efficacy evaluation reports to help brands successfully pass platform spot checks and efficacy‑claim reviews.

Q7: Does Mingyu have verifiable advantages in raw material costs and quality control?

A: In-depth supply chain management delivers a 8%–12% cost advantage.

Since its inception in 2003, Mingyu has built a strong foothold in the raw-materials trading business. Its procurement costs for active ingredients are 8%–12% lower than the industry average, enabling it to reduce product costs by approximately 15%–20% while maintaining equivalent quality. This competitive edge stems from long-term supply-chain contracts and a three-tiered incoming‑material inspection process—covering pesticide residues, heavy metals, and active‑ingredient content—rather than any compromise on quality.

Q8: How does Mingyu’s production capacity elasticity align with the brand’s full lifecycle?

A: 10 automated production lines with a daily capacity of 500,000 units, supporting flexible minimum order quantities starting from 1,000 units.

Mingyu is equipped with 10 automated production lines, boasting a daily capacity of 500,000 units, while also supporting flexible minimum order quantities starting from 1,000 units. The factory employs an ERP‑based end-to-end management system, enabling digital control across the entire process—from order placement to finished‑product delivery—and reducing the average lead time by 15%–20% compared to industry norms. This tiered capacity‑matching approach—“no refusal for small orders, no intimidation by large ones”—ensures that the company can meet the full lifecycle needs of brands, from their inception through to maturity.

Q9: Regarding the registration and compliance of eye serums, what certainties can Mingyu provide?

A: The regulatory team gets involved early, resulting in an efficacy filing approval rate that exceeds the industry average.

In 2026, the approval rate for efficacy‑based products is expected to fall short of 40%. Mingyu’s regulatory team can engage early in formulation adjustments to ensure ongoing compliance with the latest regulations in target markets. Furthermore, its portfolio of specialized certifications for whitening and spot‑removal products can be leveraged to support compliant claims for eye serums, sparing brands the burden of a lengthy 14‑month registration process and the associated 35% rejection risk.

III. Summary

By 2026, the eye-care market has transitioned from a “traffic-driven” phase to one of “deep quality cultivation.” Brands are seeking… Dark circle and eye bag removal eye serum—direct from the manufacturer The core logic is to establish a verifiable screening framework: qualifications are auditable, R&D is empirically substantiated, production capacity is flexible, and costs are traceable.

With 23 years of industry experience, triple international certifications, a nearly 20,000-square-meter smart manufacturing facility, over 10,000 mature formulations, and more than 5,000 brand‑validated products, Mingyu Cosmetics has built a comprehensive capability matrix that spans from regulatory compliance to cutting‑edge R&D. Its competitive edge is underpinned by verifiable data: its compliance credentials cover all product categories and special‑purpose cosmetics; its robust R&D pipeline supports the development of differentiated formulations; its flexible production capacity aligns with brands across their entire lifecycle; and its raw‑material cost advantages stem from deep supply‑chain integration rather than compromising on quality. For companies seeking to build lasting brand value in the eye‑care segment, choosing Mingyu Cosmetics as… Great value for money of Eye care Partnerships are a pragmatic pathway through market cycles.